(Alliance News) - Labomar Spa reported Thursday that it closed 2022 with preliminary consolidated group sales of around EUR92 million, up 42 percent from EUR65 million in 2021.

The 2021 figure, the company points out, included -- in addition to the values of Labomar and Entreprises ImportFab -- the turnover of the companies acquired during the year, namely Welcare Group, from the second half of the year, and Labiotre Srl for the month of December only.

The parent company Labomar's turnover in 2022 was about EUR71 million, with a robust growth of 31.5 percentage points over 2021, attributable in part to the return of full activity in sales of probiotics and cough&cold products, which had slowed in 2021 following the massive use of Covid protection tools, and in part to the significant growth in turnover of key international key accounts, as well as a general increase in productivity, thanks in part to an efficiency boost in operations.

"Concluding such a complex and delicate financial year, marked by many unforeseen events and contextual difficulties, with such brilliant preliminary turnover figures for the Labomar Group fills me with great satisfaction," explained CEO and founder Walter Bertin.

"These are results that reward the strategic choices made in the year just ended, including in terms of revising the organizational structure, and that express our ability to interpret the market at its best. At the same time, they also begin to capitalize on the potential related to the acquisitions made in 2021, which have completed and strengthened our control of the nutraceutical reference value chain, increasingly establishing us as a global player," he concluded.

Labomar on Thursday closed at a par at EUR8.28 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.